(Q37719683)

English

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

scientific article published on 17 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

0 references

Coagulation factor VIII

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

object named as

G Young

7

0 references

object named as

M Marcucci

6

0 references

object named as

A Iorio

1

0 references

Pier Mannuccio Mannucci

18

object named as

P M Mannucci

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

author name string

S Halimeh

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

S Holzhauer

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

N Goldenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

E Marchesini

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

C Bidlingmaier

8

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

L R Brandao

9

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

C E Ettingshausen

10

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

A Gringeri

11

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

G Kenet

12

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

R Knöfler

13

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

W Kreuz

14

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

K Kurnik

15

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

D Manner

16

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

E Santagostino

17

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

U Nowak-Göttl

19

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

publication date

17 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1256-1265

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Paediatric care of the child with haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

The epidemiology of inhibitors in haemophilia A: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03823.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2010.03823.X

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37719683&oldid=2114688016"